Compare McDonald's Corp (MCD) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McDonald's Corp vs Travere Therapeutics Inc. Common Stock — how do they compare? McDonald's Corp trades at $239.81 (market cap $166.87B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: McDonald's Corp is far larger — about 34.2× Travere Therapeutics Inc. Common Stock's market cap, and McDonald's Corp pays a 3.27% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold McDonald's Corp for 165 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| MCD | TVTX | |
|---|---|---|
Market Cap | $166.87B | $4.88B |
Volume | 4,543,119 | 1,668,577 |
Sector | Consumer Cyclical | Health |
52-Week High | $341.06 | $67.52 |
52-Week Low | $230.88 | $26.79 |
Typical Hold Time | 165 Days | 0 Days |
Enterprise Value | $220.64B | $5.01B |
Dividend Yield | 3.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McDonald's (MCD) trades at $235.65, up 0.18% on the day, with a bearish technical signal despite recent earnings beats. The company reported strong Q2 2026 EPS of $3.38, beating expectations, and maintains robust profitability with a 31.72% net income margin. Recent news highlights McDonald's new 'NEXT' growth strategy focusing on automation and menu innovation to win back customers amid competitive pressures.
The stock offers a compelling long-term opportunity with 58.7% analyst buy ratings and a $284.70 consensus price target, representing 21% upside. Key risks include inflationary pressures on franchisee margins and high debt levels. The current valuation at 19.16x P/E appears reasonable given the company's stable cash flows and dividend consistency.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
